Surrey Heartlands

Joint Formulary & PAD

Rosuvastatin calcium - Lipid modification

You are here : Home > Formulary Search > Rosuvastatin calcium - Lipid modification

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
Restrictions / Comments :

Documentation

Webpage
National Guidance for Lipid Management for Primary and Secondary Prevention of CVD (NHS England AAC programme)
Webpage
Statin Intolerance Pathway (NHS England AAC programme)
Webpage
NICE Clinical guideline [CG238] : Cardiovascular disease: risk assessment and reduction, including lipid modification
Information
Rosuvastatin and fibrate update following clarification from NICE - Oct 2014

PAD Profile

ChemicalSubstance :
Rosuvastatin calcium
Indication :
Lipid modification
Group Name :
Keywords :
Statins, primary hypercholesterolaemia, mixed dyslipidaemia, familial hypercholesterolaemia, high cholesterol, raised cholesterol, lipid lowering, lipid-lowering
Brand Names Include :
Crestor
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Lipid modification
Supporting Documents :
4

Other Indications

Below are listed other indications that Rosuvastatin calcium is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Lipid modification.

Committee Recommendations (1)

01 Oct 14 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Rosuvastatin is not a cost-effective treatment option for most patients and should be reserved for a small number of individual patients where high-intensity statin therapy is appropriate but the alternatives are not tolerated or are contraindicated.

Rosuvastatin should ONLY be considered as GREEN on the traffic light system for these individual patients.

NICE published CG 181 in July 2014 to update and replace NICE CG 67 and NICE TA 94 (statins for the prevention of cardiovascular events). This new NICE guidance does not mention rosuvastatin so the PCN sought clarification from NICE - see update following clarification from NICE below.

If statin therapy is considered appropriate the guidelines recommend using atorvastatin 20mg for primary prevention and atorvastatin 80mg for secondary prevention.